ArticleJournal for immunotherapy of cancer2019
EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapy.
Kerstin Kapp et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
6 papers cite it
this papercites it